向日葵被立案调查

Core Viewpoint - The article discusses the restructuring plan of Zhejiang Sunflower Health Technology Co., Ltd. (Sunflower), which has come under scrutiny due to misleading statements regarding its actual production capacity and business model, leading to an investigation by the Zhejiang Securities Regulatory Bureau [1][4]. Group 1: Restructuring Plan and Investigation - On September 22, 2025, Sunflower disclosed a restructuring plan involving the acquisition of 100% equity in Xipu Materials, a semiconductor company, and a 40% stake in Beid Pharmaceutical, along with raising supporting funds [4]. - The Zhejiang Securities Regulatory Bureau initiated an investigation after concerns were raised about the actual production capacity of Xipu Materials, which was previously reported to lack real production capabilities [4][5]. - The restructuring plan has been questioned for potentially containing misleading information, prompting a thorough investigation to maintain order in the mergers and acquisitions market [1]. Group 2: Market Reaction and Financial Performance - Following the announcement of the restructuring plan, Sunflower's stock price initially rose, reaching a peak of 10.28 CNY, but subsequently fell, closing at 6.2 CNY on January 14, 2026, representing a nearly 28% decline from its highest point [5]. - As of January 14, 2026, Sunflower's total market capitalization was reported at 8 billion CNY [5]. - The Shenzhen Stock Exchange issued a notice to Sunflower on December 26, 2025, requesting verification of Xipu Materials' production capacity and potential impacts on competition and independence due to the restructuring [5].